当前位置：
X-MOL 学术
›
Nat. Microbiol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.
Nature Microbiology ( IF 28.3 ) Pub Date : 2017-Oct-01 , DOI: 10.1038/s41564-017-0011-8 Teddy John Wohlbold 1, 2 , Kira A Podolsky 3 , Veronika Chromikova 1 , Ericka Kirkpatrick 1, 2 , Veronica Falconieri 3 , Philip Meade 1, 2 , Fatima Amanat 1 , Jessica Tan 1, 2 , Benjamin R tenOever 1 , Gene S Tan 1 , Sriram Subramaniam 3 , Peter Palese 1, 4 , Florian Krammer 1
Nature Microbiology ( IF 28.3 ) Pub Date : 2017-Oct-01 , DOI: 10.1038/s41564-017-0011-8 Teddy John Wohlbold 1, 2 , Kira A Podolsky 3 , Veronika Chromikova 1 , Ericka Kirkpatrick 1, 2 , Veronica Falconieri 3 , Philip Meade 1, 2 , Fatima Amanat 1 , Jessica Tan 1, 2 , Benjamin R tenOever 1 , Gene S Tan 1 , Sriram Subramaniam 3 , Peter Palese 1, 4 , Florian Krammer 1
Affiliation
A substantial proportion of influenza-related childhood deaths are due to infection with influenza B viruses, which co-circulate in the human population as two antigenically distinct lineages defined by the immunodominant receptor binding protein, haemagglutinin. While broadly cross-reactive, protective monoclonal antibodies against the haemagglutinin of influenza B viruses have been described, none targeting the neuraminidase, the second most abundant viral glycoprotein, have been reported. Here, we analyse a panel of five murine anti-neuraminidase monoclonal antibodies that demonstrate broad binding, neuraminidase inhibition, in vitro antibody-dependent cell-mediated cytotoxicity and in vivo protection against influenza B viruses belonging to both haemagglutinin lineages and spanning over 70 years of antigenic drift. Electron microscopic analysis of two neuraminidase-antibody complexes shows that the conserved neuraminidase epitopes are located on the head of the molecule and that they are distinct from the enzymatic active site. In the mouse model, one therapeutic dose of antibody 1F2 was more protective than the current standard of treatment, oseltamivir, given twice daily for six days.
更新日期：2017-08-21
京公网安备 11010802027423号